TAIPEI, Taiwan – Taipei-based OBI Pharma Inc. has entered into a deal with Merck Sharp & Dohme (MSD) for the development and commercialization in Taiwan of its narrow-spectrum macrocyclic antibiotic Dificid (fidaxomicin), which is used to treat Clostridium difficile-associated diarrhea (CDAD).